Renu Virmani

GLOBAL EXPERT EXCHANGE

08:00 – 10:00  Catheter-based treatment of hypertension, heart failure and beyond – where do we stand, where do we go?
   CHAIRMAN:
   Felix Mahfoud
   Horst Sievert
   MODERATOR:
   Thomas Zeller
   Paul Sobotka
   Roland Schmieder
   Michael Böhm
   Oliver Vonend

09:24 – 09:31  Blood pressure-lowering interventions beside renal denervation – what is on the horizon?
   Horst Sievert

09:17 – 09:24  Turn the page for hypertension and let’s go for heart failure and arrhythmias
   Michael Böhm

09:10 – 09:17  Going to the source: A disruptive approach to renal denervation with the non-vascular Verve system
   Richard Heuser

09:31 – 09:38  Treatment of resistant hypertension by creation of an AV anastomosis: the pathophysiologic basis and principle of treatment
   Paul Sobotka

09:38 – 09:45  Orchestrating sympathovagal balance with Barostim
   Navid Madershahian

09:52 – 10:00  Discussion and conclusion

09:45 – 09:52  Barostim: Clinical evidence in resistant hypertension and heart failure
   Jochen Müller-Ehmsen

09:03 – 09:10  Preliminary results of RETREAT (renal denervation with ultrasound after failed radiofrequency denervation)
   Horst Sievert

08:56 – 09:03  Late results of radiofrequency denervation and assessment of vessel patency
   Yvonne Bausback

We are asking all faculty members to strictly respect the given time limits.
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:21</td>
<td>What to learn from recent clinical trials: Symplicity HTN-3, FRENCH-DENERV-HTN, PRAGUE-15?</td>
<td>Thomas Zeller</td>
</tr>
<tr>
<td>08:14</td>
<td>How does renal artery anatomy effect the outcome of RDN procedures?</td>
<td>Britta Vogel</td>
</tr>
<tr>
<td>08:07</td>
<td>From bench to bedside: how and where to treat the renal artery?</td>
<td>Felix Mahfoud</td>
</tr>
<tr>
<td>08:28</td>
<td>Renal denervation – dead or alive? The view point of a nephrologist/hypertenion specialist</td>
<td>Oliver Vonend</td>
</tr>
<tr>
<td>08:35</td>
<td>Recent clinical findings and how they changed my patient selection: who is the ideal candidate?</td>
<td>Philipp Lurz</td>
</tr>
<tr>
<td>08:49</td>
<td>Renal denervation in patients with impaired kidney function – results from the Heidelberg RDN registry</td>
<td>Erwin Blessing</td>
</tr>
<tr>
<td>08:42</td>
<td>What is needed now? New clinical trials that would change my clinical practice</td>
<td>Roland Schmieder</td>
</tr>
<tr>
<td>08:00</td>
<td>Renal denervation: what has anatomy taught us?</td>
<td>Renu Virmani</td>
</tr>
</tbody>
</table>

We are asking all faculty members to strictly respect the given time limits.
PROGRAMME

LEIPZIG
INTERVENTIONAL COURSE

MAIN ARENA 1

**09:30 – 11:00**

**Critical limb ischemia treatment 2014: Lessons learned, current status and future perspectives**

Chairman:
Dierk Scheinert
Peter Schneider

Moderator:
Iris Baumgartner

Renu Virmani
Andrew Holden
Yoshiaki Yokoi
Michael Jaff

10:25 – 10:30
Panel discussion and vote

10:20 – 10:25
Ongoing trials and future concepts for local drug delivery in BTK arteries
Dierk Scheinert

10:15 – 10:20
Safety of Paclitaxel balloon coatings: Insights from a pathologist
Renu Virmani

10:30 – 10:45
Live case transmission from Leipzig part II
Renu Virmani

10:45 – 10:50
Destiny II: 12 months results with long segment DES treatment in BTK arteries
Marc Bosiers

10:55 – 11:00
Initial experience with absorbable drug-eluting vascular scaffolds in BTK arteries
Ramon Varcoe

10:50 – 10:55
PES BTK 70: 12 months results with a paclitaxel-coated self-expandingstent in BTK arteries
Marc Bosiers

10:10 – 10:15
One year after In.Pact Deep: Lessons learned from a failed trial
Thomas Zeller

10:10 – 11:00
Drug-coated balloons for BTK disease in critical limb ischemia – a failed concept?

09:40 – 09:45
The BEST-CLI Trial: Open vs. endovascular therapy for critical limb ischemia
Michael Jaff

09:40 – 10:10
The Angiosome concept: Pro and cons

We are asking all faculty members to strictly respect the given time limits.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:35 – 09:40</td>
<td>Real world CLI practice: Update from the CRITISCH registry</td>
<td>Theodosios Bisdas</td>
</tr>
<tr>
<td>09:45 – 09:50</td>
<td>Revascularization of the wound-related artery is key</td>
<td>Osamu Iida</td>
</tr>
<tr>
<td>09:50 – 10:00</td>
<td>Live case transmission from Leipzig part I</td>
<td></td>
</tr>
<tr>
<td>10:05 – 10:10</td>
<td>Panel discussion and vote</td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:05</td>
<td>There is no proof for the angiosome concept</td>
<td>Peter Huppert</td>
</tr>
<tr>
<td>09:30 – 09:35</td>
<td>The rationale for the “Endovascular First” concept and how to implement it</td>
<td>Peter Schneider</td>
</tr>
</tbody>
</table>

We are asking all faculty members to strictly respect the given time limits.
MAIN ARENA 1

13:30 – 15:00  Symposium: Lutonix® DCB – Discussion on pre-clinical safety studies, new insights from LEVANT2, Real World experience and the role of DCB in treatment of critical limb ischemia supported with an educational grant from CR BARD

Chairman:
Michael Jaff

Moderator:
Renu Virmani
Marcus Thieme
Marianne Brodmann
Jihad Mustapha

14:40 – 14:47  Role of DCBs in treating critical limb ischemia and the enrollment update on-going Lutonix® BTK clinical trial
Marianne Brodmann

14:47 – 14:54  Discussion on physiology of CLI in utility of DCB in below-the-knee procedures
Jihad Mustapha

14:54 – 15:00  German single center experience with Lutonix® DCB in BTK
Sabine Steiner

14:16 – 14:40  Live case transmission from Leipzig

14:09 – 14:16  A first look and interim analysis of 12 month outcomes from the Real World Global SFA registry
Marcus Thieme

13:37 – 14:02  Live case transmission from Leipzig

14:02 – 14:09  New insights from LEVANT2: Randomized 12 month data and post hoc analysis
Dierk Scheinert

13:30 – 13:37  Not all DCBs are created equal: Side by side pre-clinical safety evaluation of leading DCBs
Renu Virmani

We are asking all faculty members to strictly respect the given time limits.
Thursday, January 29, 2015

**DISCUSSION FORUM**

12:30 – 13:30 **The great debate: Are all DCB equal?**

**CHAIRMAN:**
- Michael Jaff
- Dierk Scheinert

**DISCUSSANT:**
- Gunnar Tepe
- Renu Virmani
- Stephan Duda
- Marianne Brodmann

13:05 – 13:12

DCB are still a valid option to solve the challenge of BTK vessel patency: Lutonix BTK trials are continuing

Marianne Brodmann

13:12 – 13:30

Discussion and conclusion

12:58 – 13:05

Lessons learned from INPACT.Deep and why we should stay away from DCB for BTK interventions

Erich Minar

12:51 – 12:58

What’s next to come in the drug delivery space: Ongoing DCB programmes

Stephan Duda

12:37 – 12:44

Lacking head-to-head trials comparing different DCB studies is comparing apples and oranges – Results have been substantially affected by trial design

12:44 – 12:51

The relevance of Paclitaxel dose and coating for efficacy and safety

Renu Virmani

12:30 – 12:37

There are clear differences in DCB outcomes in the SFA for various coatings – DCB are not equal!

Gunnar Tepe

---

*We are asking all faculty members to strictly respect the given time limits.*